Drug conjugates comprising antibodies against claudin 18.2

US11541127B2 · kind B2 · utility

Assignees

• ASTELLAS PHARMA INC. · JP
• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Ugur Sahin · Mainz, DE
• Ozlem Tureci · Homburg, DE
• Korden Walter · Mainz, DE
• Maria Kreuzberg · Mainz, DE
• Rita Mitnacht-Kraus · Friedberg, DE
• Fabrice Le Gall · Mainz, DE
• Stefan Jacobs · Mainz, DE

Key dates

• Filing date: Apr 13, 2016
• Grant date: Jan 3, 2023
• Expiry date: Apr 22, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.